Clinical treatment for hepatitis C reverses CYP2C19 inhibition (2021)
Pippa, Leandro Francisco 
; Vieira, Carolina Pinto; Caris, Juciene Aparecida; Rocha, Adriana; Garcia, Camile Prates; Rezende, Rosamar Eulira Fontes; Lanchote, Vera Lucia
Source: British Journal of Clinical Pharmacology. Unidade: FCFRP
Subjects: ANTIVIRAIS, CITOCROMO P-450, FLAVIVIRIDAE, HEPATITE C, HEPATITE CRÔNICA, FARMACOTERAPIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PIPPA, Leandro Francisco et al. Clinical treatment for hepatitis C reverses CYP2C19 inhibition. British Journal of Clinical Pharmacology, v. 87, n. 10, p. 4013-4019, 2021Tradução . . Disponível em: https://doi.org/10.1111/bcp.14829. Acesso em: 06 nov. 2024.APA
Pippa, L. F., Vieira, C. P., Caris, J. A., Rocha, A., Garcia, C. P., Rezende, R. E. F., & Lanchote, V. L. (2021). Clinical treatment for hepatitis C reverses CYP2C19 inhibition. British Journal of Clinical Pharmacology, 87( 10), 4013-4019. doi:10.1111/bcp.14829NLM
Pippa LF, Vieira CP, Caris JA, Rocha A, Garcia CP, Rezende REF, Lanchote VL. Clinical treatment for hepatitis C reverses CYP2C19 inhibition [Internet]. British Journal of Clinical Pharmacology. 2021 ; 87( 10): 4013-4019.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1111/bcp.14829Vancouver
Pippa LF, Vieira CP, Caris JA, Rocha A, Garcia CP, Rezende REF, Lanchote VL. Clinical treatment for hepatitis C reverses CYP2C19 inhibition [Internet]. British Journal of Clinical Pharmacology. 2021 ; 87( 10): 4013-4019.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1111/bcp.14829
